This paper is only available as a PDF. To read, Please Download here.
REFERENCES
- Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease. Harvard University Press, Cambridge, MA1980: 1-381
- The Lipid Research Clinics Coronary Primary Prevention Trial Results. 1. Reduction in the incidence of coronary heart disease.JAMA. 1988; 251: 351-364
- ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogen-esis produced by Penicillium citrinum.J. Antibiot. (Japan). 1976; 29: 1346-1348
- Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B, fungal metabolites, having hypocholesterolemic activity.FEBS Lett. 1976; 72: 323-326
- Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.Eur. J. Biochem. 1978; 87: 313-321
- Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.Atherosclerosis. 1979; 32: 307-313
- Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.Lipids. 1979; 14: 585-589
- Therapeutic effects of ML-236B in primary hypercholesterolemia.Atherosclerosis. 1980; 35: 259-266
- HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.N. Engl. J. Med. 1988; 319: 24-33
- HMG-CoA reductase inhibitors.Curr. Opin. Lipidol. 1992; 3: 22-28
- Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B..N. Engl. J. Med. 1990; 323: 1289-1298
- Influence of nicotinic acid on serum cholesterol in man.Arch. Biochem. Biopkys. 1955; 54: 558-559
- Plasma cholesterol lowering action of bile acid binding polymers in experimental animals.J. Lipid Res. 1960; 1: 469-473
- Modification of metabolism and distribution of lipids by ethyl chlo-rophenoxyisobutyrate.Nature. 1962; 194: 948-949
- Lowering of serum lipid concentrations. Mechanisms used by unsaturated fats, nicotinic acid and neomycin: excretion of sterols and bile acids.Arch. Intern. Med. 1960; 105: 512-517
- Reduction of blood cholesterol in man.Circulation. 1953; 7: 702-706
- Effects of an inhibitor of cholesterol biosynthesis, triparanol (MER-29), in subjects with and without coronary artery disease.Boston Med. Quart. 1959; 10: 37-44
- Reduction of serum cholesterol by sodium D-thyroxine.A.M.A. Arch. Intern. Med. 1960; 105: 830-842
- The effects of estrogens on the serum cholesterol of male rats.Symp. Deut. Ges. En-dokrinol. 1959; : 430-432
- AMA Drug Evaluations. 3rd ed. PSG Publishing Company, Littleton, MA1977: 153-174
- Cataracts in patients treated with triparanol.JAMA. 1962; 181: 339-340
- Regulation of cholesterol metabolism.N. Engl. J. Med. 1970; 282 (1179-1183, 1241–1249): 1128-1138
- Regulation of cholesterol biosynthesis in normal and malignant tissues.Curr. Top. Cell. Regul. 1970; 2: 65-100
- Effect of cholesterol feeding and fasting on sterol synthesis in seventeen tissues of the rat.J. Lipid Res. 1967; 8: 97-104
- Cholesterol synthesis in the squirrel monkey: relative rates of synthesis in various tissues and mechanisms of control.J. Clin. Invest. 1968; 47: 166-174
- Feedback control of mevalonate synthesis by dietary cholesterol.J. Biol. Chem. 1966; 241: 602-609
- Improved assay of 3-hydroxy-3-methylglutaryl coenzyme A reductase.J. Lipid Res. 1971; 12: 512-515
- The biosynthesis of mevalonic acid from 1-14C-acetate by rat liver enzyme system.J. Biol. Chem. 1959; 234: 2835-2840
- Citrinin, an inhibitor of cholesterol synthesis.J. Antibiot. (Japan). 1976; 29: 841-843
- Time-dependent, irreversible inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase by the antibiotic citrinin.Biochim. Biophys. Acta. 1977; 488: 97-101
- Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum.J. Chem. Soc. Perkin I. 1976; : 1165-1170
- Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase.J. Med. Chem. 1985; 28: 401-405
- Kinetic analysis of the reaction catalyzed by rat-liver 3-hydroxy-3-methylglutaryl coenzyme A reductase using two specific inhibitors.Eur. J. Biochem. 1979; 98: 195-201
- Mode of interaction of β-hydroxy-β-methylglutaryl coenzyme A reductase with strong binding inhibitors.Compactin and related compounds.Biochemistry. 1985; 24: 1364-1376
- Mevalonolactone derivatives as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.Chem. Pharm. Bull. (Japan). 1980; 28: 1509-1525
- Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-meythylglutaryl coenzyme A reductase.J. Antibiot. (Japan). 1979; 33: 334-336
- Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and cholesterol-lowering agent.Proc. Natl. Acad. Sci. USA. 1980; 77: 3957-3961
- Microbial hydroxylation of compactin (ML-236B) and monacolin K..J. Antibiot. (Japan). 1985; 38: 605-609
- Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts by lipoproteins.Proc. Natl. Acad. Sci. USA. 1973; 70: 2162-2166
- Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity.Proc. Natl. Acad. Sci. USA. 1974; 71: 788-792
- Lipoprotein receptors, cholesterol metabolism, and atherosclerosis.Arch. Pathol. 1975; 99: 181-184
- Receptor-mediated control of cholesterol metabolism.Science. 1976; 191: 150-154
- Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase.J. Biol. Chem. 1978; 253: 1121-1128
- Specific inhibition of des-mosterol synthesis by ML-236B in mouse LM cells grown in suspension in a lipid-free medium.J. Med. Sci. Biol. (Japan). 1978; 31: 225-233
- Specific nonsterol inhibitors of HMG-CoA reductase.in: Preiss B. Regulation of HMG-CoA reductase. Academic Press, New York, NY1985: 49-78
- Essential role for mevalonate synthesis in DNA replication.Proc. Natl. Acad. Sci. USA. 1979; 76: 5056-5060
- Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor.J. Biol. Chan. 1980; 255: 5134-5140
- A study of the influence of mevalonic acid and its metabolites on the morphology of Swiss 3T3 cells.J. Cell Biol. 1982; 95: 144-153
- Evidence for post-translational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins.J. Biol. Chem. 1984; 256: 10175-10180
- All ras proteins are polyisoprenylated but only some are palmitoylated.Cell. 1989; 57: 1167-1177
- Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans.Science. 1989; 245: 379-385
- Evidence for modification of lamin B by a product of mevalonic acid.J. Biol. Chem. 1988; 263: 5997-6000
- Incorporation of a product of mevalonic acid metabolism into proteins of Chinese hamster ovary cell nuclei.J. Cell Biol. 1988; 107: 1307-1316
- The ras oncogenes —an important regulatory element in lower eu-karyotic organisms.Micro. Rev. 1989; 53: 171-185
- Regulation of the mevalonate pathway.Nature. 1990; 343: 425-430
- Role for isoprenoid lipids in the localization and function of an oncoprotein.New Biol. 1990; 2: 219-226
- The prenylation of proteins.Curr. Opin. Lipidol. 1992; 2: 118-124
- Appearance of crystalloid endoplasmic reticulum in compactin-resistant Chinese hamster cells with a 500-fold increase in 3-hydroxy-3-methylglutaryl coenzyme A reductase.Proc. Natl. Acad. Sci. USA. 1982; 79: 1185-1189
- Amplification of the gene for 3-hydroxy-3-methylglutaryl coenzyme A reductase, but not for the 53-kDa protein, in UT-1 cells.J. Biol. Chem. 1983; 258: 8462-8469
- Molecular cloning of 3-hydroxy-3-methylglutaryl coenzyme A reductase and evidence for regulation of its mRNA.Proc. Natl. Acad. Sci. USA. 1982; 79: 7704-7708
- Nuclotide sequence of 3-hydroxy-3-methylglutaryl coenzyme A reductase, a glycoprotein of endoplasmic reticulum.Nature. 1984; 308: 613-617
- Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and its mRNA in rat liver as studied with a monoclonal antibody and a cDNA probe.J. Biol. Chem. 1983; 258: 8450-8455
- Domain structure of 3-hydroxy-3-methylglutaryl coenzyme A reductase, a glycoprotein of the endoplasmic reticulum.J. Biol. Chem. 1985; 260: 522-530
- Effects of ML-236B on cholesterol metabolism: lack of hypocholesterolemic activity in normal animals.Biochim. Biophys. Acta. 1979; 575: 266-276
- Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.Eur. J. Biochem. 1977; 77: 31-36
- The influence of intravenously administered surface active agents on the development of experimental atherosclerosis in rabbits.J. Exp. Med. 1951; 93: 385-398
- Cholesterol biosynthesis in preparation of liver from normal, fasting, x-irradiated, cholesterol-fed, Triton or Δ4-cholesten-3-one-treated rats.J. Biol. Chem. 1962; 243: 262-267
- Prevention of cyclic and Triton-induced increase in hydroxymethyl-glutaryl coenzyme A reductase and sterol synthesis by puromycin.J. Biol. Chem. 1969; 244: 2299-2305
- Triton hypercholesterolemia: cause or consequence of augmented cholesterol synthesis.Am. J. Physiol. 1963; 204: 1100-1102
- Mechanism for elevation of hepatic cholesterol synthesis and serum cholesterol levels in Triton WR-1339-induced hyperlipidemia.Biochim. Biophys. Acta. 1977; 489: 119-125
- Effects of ML-236B, a competitive inhibitor of 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase, on cholesterol metabolism.Adv. Exp. Med. Biol. 1978; 109 (Abstract.): 376
- Two Japanese kindreds of familial hypercholesterolemia including homozygous cases. A report of cases, and studies on serum lipoproteins and enzymes.Jpn. J. Med. 1978; 17: 230-239
- Treatment of hypercholesterolemia with an HMG-CoA reductase inhibitor (CS-500). I. Phase I study in normal subjects.Geriat. Med. (Japan). 1979; 17: 1564-1570
- Treatment of hypercholesterolemia with an HMG-CoA reductase inhibitor (CS-500).II. Determination of unit weight effect and daily doses by an integration method and observation of safety in initial stage.Geriat. Med. (Japan). 1980; 18: 104-112
- Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hyper-cholesterolemia.N. Engl. J. Med. 1981; 305: 478-482
- Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia: additive effects of compactin and cholestyramine.N. Engl. J. Med. 1983; 308: 609-613
- Combined drug therapy — cholestyramine and compactin —for familial hypercholesterolemia.Int. J. Clin. Pharmacol. Ther. Toxicol. 1984; 22: 493-497
- Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog.Proc. Natl. Acad. Sci. USA. 1981; 78: 1194-1198
- Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heter-ozygotes.Proc. Natl. Acad. Sci. USA. 1983; 80: 4124-4128
- Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentration or turnover.J. Pediatr. 1988; 113: 383-392
- The low-density lipoprotein pathway and its relation to atherosclerosis.Annu. Rev. Biochem. 1977; 46: 897-930
- Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits.Proc. Natl. Acad Sci. USA. 1986; 83: 8370-8374
- Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.J. Lipid Res. 1985; 26: 1464-1475
- Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance.Proc. Natl. Acad. Sci. USA. 1984; 81: 2538-2542
- Plasma mevalonate as a measure of cholesterol synthesis in man.J. Clin. Invest. 1984; 74: 795-804
- Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase, in healthy volunteers.J. Clin. Invest. 1982; 69: 913-919
- Hypocholestero-lemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.J. Clin. Invest. 1984; 74: 1972-1978
- Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia.Clin. Pharmacol. Ther. 1986; 40: 338-343
- Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: a multicenter study.Ann. Intern. Med. 1987; 107: 609-615
- Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.Ann. Intern. Med. 1984; 101: 598-604
- Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia.Ann. Intern. Med. 1985; 103: 339-343
- Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia: a multicenter study.JAMA. 1986; 256: 2829-2834
- Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia.Am. J. Cardiol. 1986; 57: 933-939
- Preliminary report. Treatment of type 3 hyperlipoproteinemia with mevinolin.Metabolism. 1986; 35: 97-98
- Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B..Atherosclerosis. 1988; 70: 131-143
- Lovastatin for lowering cholesterol levels in noninsulin-dependent diabetes melli-tus.N. Engl. J. Med. 1988; 313: 81-86
- Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.Kidney Int. 1988; 33: 1160-1168
- Combination therapy for familial combined hyperlipidemia.Ann. Intern. Med. 1988; 109: 25-32
- Effects of fluvastatin (XU-62320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans.Atherosclerosis. 1991; 87: 147-157
- Bay W 6228: a new generation HMG-CoA reductase inhibitor. I. Synthesis and structure activity relationships. XI International Symposium on Drugs Affecting Lipid Metabolism, Florence, Italy, 1992 (Abstract)
- Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine-and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-hep-tanoic) acids.J. Med. Chem. 1990; 33: 52-60
- 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin.J. Med. Chem. 1986; 29: 849-852
- Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolemia.Lancet. 1986; 2: 936-939
- Synvinolin in hypercholesterolemia.Lancet. 1986; 2: 390-391
- Lovastatin and simvastatin.Cah. Nutr. Diet. 1988; 23: 231-234
- Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II).Am. J. Cardiol. 1989; 63: 682-686
- Simvastatin study group. Safety, tolerability, and efficacy of simvastatin and fenofibrate — a multicenter study.Cardiology. 1990; 77: 50-57
- Simvastatin - a review of its pharmacological properties and therapeutic potential in hypercholesterolemia.Drugs. 1990; 40: 583-607
- Improvement in the regulation of cellular cholesterogenesis in diabetes: the effect of reduction in serum cholesterol by simvastatin.Diabet. Med. 1991; 8: 151-156
- CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species.Biochìm. Bìophys. Acta. 1986; 877: 50-60
- Effects of CS-514 on serum lipoprotein lipid and apoprotein level in patients with familial hypercholesterolemia.Metabolism. 1987; 36: 475-479
- The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects.JAMA. 1987; 257: 3088-3093
- Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.Atherosclerosis. 1990; 85: 81-89
- The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolemia.J. Intern. Med. 1990; 228: 261-266
- Pravastatin therapy in primary moderate hypercholesterolemia: changes in metabolism of apolipoprotein B-containing lipoproteins.J. Intern. Med. 1990; 227: 81-94
- Nutrition and therapeutics: editorial overview.Curr. Opin. Lipidol. 1992; 3: 1-4
- Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.Am. J. Cardiol. 1987; 60: 33G-42G
Article info
Publication history
Published online: November 01, 1992
Identification
Copyright
© 1992 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.
User license
Creative Commons Attribution (CC BY 4.0) | How you can reuse
Elsevier's open access license policy

Creative Commons Attribution (CC BY 4.0)
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy